Allograft Inflammatory Factor-1 (AIF1) is a cytoplasmic scaffold protein that contains Ca 2+ binding EF-hand and PDZ interaction domains important for mediating intracellular signaling com- 
In this study, silencing of AIF1 in DC restrained CD8 + T cells effector functions and, in turn, redirected them to functionally suppressive IL-10 producing CD122 + PD-1 + regulatory T cells. This investigation provides additional evidence that AIF1 expression in DC is instrumental in governing adaptive immune responses and that its loss leads to tolerance.
MATERIALS AND METHODS

Mice
Mice were purchased from Jackson Laboratory and bred in-house in pathogen free settings at Howard University. All animal procedures performed were approved by the Institutional Animal Care and Use Committee. C57BL/6 (wild-type; WT) mice were used as a source of bone marrow and as recipients for in vivo adoptive transfer experiments. Transgenic C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) and B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II) mice were used as a source of CD8 + T cells that recognize ovalbumin peptide residues 257-264 (OVA 257-264; SIINFEKL ) and CD4 + T cells that recognize residues 323-339 (OVA 323-339 ), respectively. CD31 (390) was purchased from BD Biosciences (San Diego, CA) and AIF1 (EPR16588) from Abcam (Cambridge, MA). For primary unconjugated antibodies, secondary-tagged fluorochrome-labeled antibodies were prepared. These secondary antibodies were diluted to 1:1000-1:3000 working concentrations and 10 l were added per 2 × 10 5 cells. Cells were allowed to incubate for 1 h or overnight, followed by extensive washing. Samples were acquired using a BD FACSVerse or Accuri C6 flow cytometric analyzer. Datasets were analyzed using FlowJo v10 (TreeStar, Ashland, OR). Respective isotype controls and/or fluorochrome-labeled isotype controls were used in all assays. Gating strategies were established based on respective isotype controls. For proliferation assays, gates were established based on unstimulated labeled cells.
Flow cytometry and antibodies
Generation of bone marrow-derived DCs and siRNA knockdown
Femurs and tibias were harvested from C57BL/6 (WT) mice between 10 and 16 weeks of age to generate bone marrow-derived DC, as described by a modified protocol of Inaba et al. 19 Briefly, bone marrow cells were cultured in IMDM (Thermo Fisher Scientific, Grand Island, NY) supplemented with 10% FBS (Thermo Fisher Scientific), 2 mM L-glutamine (Thermo Fisher Scientific), 100 U/ml penicillin/ streptomycin (Thermo Fisher Scientific), and 20 ng/ml GM-CSF for 7 days in culture. On day 5 (of the 7 day culture), cells were purified for a homogenous DC population using CD11c microbeads (Miltenyi Biotec, Auburn, CA). The approach yielded greater than 96% purity, as previously described. 18 5 ′ -GGCAAGAGAUCUGCCAUCUUG-3 ′ (Thermo Fisher Scientific), as previously described. 18, 20 Scrambled siRNA served as controls (siControl): 5 ′ -GGGCTCTACGCAGGCATTTAA-3 ′ . After electroporation of siRNA on day 5 in CD11c + -sorted DCs, cells were placed back into culture. On day 6, 24 h after siRNA transfection, DCs were matured with 250 ng/ml of LPS and cultured for an additional 24 h. On day 7, the siRNA transfected mature DCs were used to prime naïve CD8 + OT-I T cells. Flow cytometric analyses confirmed routine transfection with siRNA to yield greater than 70% knockdown in CD11c + DCs, as previously reported. 18 
Isolation of CD8 + T cells for in vitro stimulation and proliferation assays
For isolation of naïve CD8 + T cells from OT-I mice, CD4 + T cells and MHC class II + APCs were depleted by negative selection from spleen and lymph nodes using primary antibodies to CD4 and MHC class II (BioLegend) followed by secondary labeling with anti-rat IgG magnetic microbeads (Qiagen, Hilden Germany). Cells were then depleted by passing through a magnetic column. This resulted in a purity greater than 97% for CD8 + CD44 − CD62L + cells. These isolated naïve CD8 + T cells were cultured with SIINFEKL peptide-or OVA protein-pulsed siAIF1 or siControl LPS-matured DC at a ratio of 10:1, respectively. MOG protein and scrambled non-specific peptides served as controls.
Cells were pulsed for 5 h at 37 • C. All OVA protein and peptides were purchased from AnaSpec (Fremont, CA). SIINFEKL peptide was used at 0.1 or 0.3 g/ml and OVA protein at 20 g/ml. 
in vitro cytotoxic CD8 + T cell killing assays
siAIF1 or siControl DC-expanded OT-I CD8 + T cells were collected, washed, and plated with target CFSE-labeled CD4 + T cells isolated from WT mice using negative depletion approaches, as previously described. 18, 20 Briefly, the WT CD4 + T cells were split into two equal groups: SIINFEKL peptide-pulsed and scrambled control peptide- 
ELISA assays
After specific time points of cell incubations, supernatant was collected and stored at −80 • C until use. IL-10 (BioLegend), TGF (BioLegend), and IFN (BD Biosciences) ELISA kits were used following manufacturers' recommended protocols to measure cytokine expression.
Absorbance values were collected and quantified using the Synergy HT (BioTek, Winnoski, VT) multimode microplate reader.
Statistical analysis
GraphPad Prism v7.0 (GraphPad Software, La Jolla, CA) was used to determine statistical significance. Student unpaired two-tailed ttest was used to evaluate the significance of two groups. A P value ≤ 0.05 was considered statistically significant; * = <0.05, ** = <0.01, and ns = non-significant. Error bars for all figures indicate standard deviation.
RESULTS
Loss of AIF1 in DC impairs antigen-specific CD8 + T cell responses
Previous studies have shown that AIF1 expression in DC modulates immunity in CD4 + T cell subsets. 18 As a follow up, these new investiga- For SIINFEKL peptide, there was a dramatic reduction in CXCR3 + Granzyme B + CD8 + T cells from 62.7% ± 3.9 in the siControl treated group down to 17.7% ± 1.1 in the siAIF1 groups. The same trend was observed upon pulsing with OVA protein, with a reduction from 24.3% ± 2.1 in the siControl to that of 3.9% ± 0.4 in siAIF1 cohorts.
With reduced effector responses observed in the siAIF1 group, the studies next measured proliferative capacity coupled with expression of IFN , which is a hallmark cytokine for cytotoxic T cell effector responses. AIF1 knockdown DC restrained proliferation of responder CD8 + T cells (Fig. 1B) . Importantly, those T cells that were able to be expanded in the siAIF1 DC cohort had significantly lower IFN expression. Levels were reduced to 8.8% ± 0.6 in SIINFEKL peptideand 4.6% ± 1.4 in OVA protein-primed groups, in comparison with 34.8% ± 2.3 and 19.4% ± 1.1, respectively, in the siControl groups.
Lastly, the studies next collected siAIF1 DC-or siControl DC-expanded CD8 + T cells and plated them at equal numbers. Cells were then restimulated with mitogen for 5 h. Results revealed significant restrain in ability to produce IFN from siAIF1 DC-expanded CD8 + T cells in comparison with siControl DC in both peptide and protein priming conditions (Fig. 1C) . (Fig. 2A) . The siControl cohort had decreased target numbers down from 45.6% ± 0.6 in the internal control group to 24.4% ± 1.3 in SIINFEKL and to 27.9% ± 2.0 in OVA protein groups. The internal control group is target cells not pulsed with SIINFEKL peptide or OVA protein. However, restrained killing was observed by the CD8 + T cells stimulated by siAIF1 DC, where reduction from the internal control was down only to 35.6% ± 3.3 in SIINFEKL peptide and 42.0% ± 2.7 in OVA protein groups. Varying the concentration of target-to-effector ratio revealed that roughly 10-fold more siAIF1 DC-expanded CD8 + T cells were required to yield the same killing efficacy as the siControl group (Fig. 2B) . shown that CD8 + CD122 + T cell subsets can serve to both maintain homeostasis and restrain exacerbated immune pathologies. 7, 8, 25 These CD8 + Treg cells exerted suppression through IL-10 and PD-1 dominant mechanisms. In assessing onset of regulatory fates, siAIF1 DC pulsed with either SIINFEKL peptide or OVA protein resulted in increased levels of CD122 + PD-1 + subsets expanded from naïve CD8 + T cells (Fig. 3A) . In siControl DC, levels of CD122 + PD-1 + observed were 15.8% ± 0.9 and 17.3% ± 0.6 for SIINFEKL-peptide and OVA protein-pulsed groups, respectively. However, in the siAIF1 DC, studies reproducibly found higher levels of CD122 + PD-1 + populations, with 42.9% ± 3.4 expanded in the SIINFEKL peptide and 46.5% ± 4.1 in the OVA protein groups. In addition to CD8 + T cells expanded by siAIF1 DC having reduced proliferation capacity, there was also a greater proportion of IL-10 production in the few proliferating subsets when compared with subsets stimulated by siControl DC (Fig. 3B) . In the SIINFEKL peptide cohort, the siControl DC had 55.0% ± 5.1 IL-10 + proliferative subsets compared with 32.1% ± 2.9 that were negative for IL-10. However, in the siAIF1 DC cohort, 26.7% ± 1.9 were IL-10 + and only 7.1% ± 0.5 were IL-10 negative. Similar results were seen in the OVA protein expanded population. This would suggest that the siAIF1 DC expanded CD8 + T cells had a reduced overall proliferation capacity, but that the majority of the few dividing cells were producing IL-10. To further investigate IL-10 production, total CD8 + T cells expanded from either siControl or siAIF1 DC were collected and plated at equal numbers after 7 days. Cells were then stimulated with mitogens prior to assessing total release of IL-10 into the supernatant.
At equal cell number plating, CD8 + T cells expanded from siAIF1 DC produced several fold higher levels of IL-10 in comparison with the siControl group (Fig. 3C) .
AIF1 knockdown DC-primed CD8 + T cells suppress neighboring CD4 + T cell expansion
Regulatory function of the CD8 + T cells expanded by siAIF1 DC was next assessed by evaluating ability to suppress neighbor CD4 + T cell proliferation in vitro. OVA protein pulsed siControl or siAIF1 DCexpanded CD8 + T cells were cultured with OT-II isolated CFSE-labeled CD4 + T cells at varying ratios. Next, APCs pulsed with OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] peptide were used to stimulate the CFSE-labeled CD4 + T cells in the coculture; the OT-I CD8 + T cells are unresponsive to OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] peptide. Absence of the siControl or siAIF1 DC-expanded CD8 + T cells served as internal controls. Results revealed approximately a 50% reduction in CD4 + T cell proliferation, from 77.8% ± 3.9 in the siControl to 37.4% ± 2.8 in the siAIF1 cohort (Fig. 4A) . To further delineate the potential role of IL-10 or PD-1 in mediating suppression, neutralizing antibodies were added during the coculture. Neutralizing either IL-10 or PD-1 alleviated the suppressive function of the siAIF1 expanded CD8 + T cells on the proliferating responder CD4 + T cell cells. However, no significant differences were observed upon addition of neutralizing antibodies to IL-10 or PD-1 in the siControl DC groups.
Lastly, varying concentrations of CFSE-labeled CD4 + T cell responders with siControl or siAIF1 DC-expanded CD8 + T cells were measured (Fig. 4B) . As the ratio of CD8 + T cells from the siAIF1 DC cohort was reduced, the effective suppression of CD4 + T cell responder proliferation was proportionally limited.
Adoptive transfer of AIF1 knockdown DC restrains T effector responses in vivo
In vivo studies were next performed to recapture in vitro observed suppressive functions of AIF1 knockdown DC-expanded CD8 + T cells. 
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